Yeah, one of those deals where the same person recycles the same information over and over and maybe once gets lucky.
I do think if a buyout ever were to happen, which I'm not betting on, it would happen this year... before we get a ART product approved and the revenue starts to roll in. That would be the cheapest for a big pharma to do and they would have study results to look at before placing an offer.
Market Data 
Markets 
AI
